We observed that an increase in (nuclear) FGFR1 expression from HN to CRPC was associated with reduced mean disease-specific survival of 4.9 years, compared with 7.4 years in those that did not show such enhanced FGFR expression in CR tumours (P=0.018; Figure 4D). Here, FGFR1 is linked to neoplasm.